The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

Administration of quetiapine XR

The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.

Trial Locations (1)

114

Tri-Service General Hospital, National Defense Medical Center, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Tri-Service General Hospital

OTHER